Fig. 7
Combined ILEI KD and crizotinib treatment increases E-cadherin membrane localization in tumor xenografts. a, f Representative images of E-cadherin IHC on NCI-H441 (a) and NCI-H1993 (e) shCont and shILEI tumor sections of vehicle or crizotinib-treated mice. Scale bar, 100 μm. b, g E-cadherin membrane score of NCI-H441 (b) and NCI-H1993 (f) shCont and shILEI tumors of vehicle- or crizotinib-treated mice. Error bars represent SEM. Statistical significance was determined by one-way ANOVA and marked with asterisks (*p < 0.05; **p < 0.01). c, h qPCR analysis of E-cadherin mRNA expression (CDH1) in NCI-H441 (c) and NCI-H1993 (g) shCont and shILEI tumors of vehicle- or crizotinib-treated mice (n = 3 pro group). Relative expression was normalized to GAPDH and shown as fold change to vehicle treated control tumors. Error bars represent SEM. Statistical significance was determined by one-way ANOVA and marked with asterisks (*p < 0.05). d, i Western blot analysis of E-cadherin protein expression in NCI-H441 (d) and NCI-H1993 (h) shCont and shILEI tumors of vehicle- or crizotinib-treated mice (n = 3 pro group). e, j Quantification of E-cadherin protein expression from the Western blot analyses shown in panels d and i. Expression was normalized to actin loading control and shown as fold expression relative to vehicle treated shCont tumors. Error bars represent SEM. Statistical significance was determined by one-way ANOVA and marked with asterisks (*p < 0.05)